#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=2.
1-1	0-2	2.	_	_	_	_

#Text=The Role of the bHLH Proteins in Transcription
2-1	3-6	The	abstract[1]	new[1]	_	_
2-2	7-11	Role	abstract[1]	new[1]	_	_
2-3	12-14	of	abstract[1]	new[1]	_	_
2-4	15-18	the	abstract[1]|substance[3]	new[1]|new[3]	coref	5-11[0_3]
2-5	19-23	bHLH	abstract[1]|abstract|substance[3]	new[1]|new|new[3]	coref	8-7
2-6	24-32	Proteins	abstract[1]|substance[3]	new[1]|new[3]	_	_
2-7	33-35	in	abstract[1]|substance[3]	new[1]|new[3]	_	_
2-8	36-49	Transcription	abstract[1]|substance[3]|abstract	new[1]|new[3]|new	coref	3-8

#Text=The regulation of genes expression by multiple transcription factors , cofactors and chromatin regulators establish and maintains a specific state of a cell .
3-1	50-53	The	abstract[5]	new[5]	_	_
3-2	54-64	regulation	abstract[5]	new[5]	_	_
3-3	65-67	of	abstract[5]	new[5]	_	_
3-4	68-73	genes	abstract[5]|abstract	new[5]|new	coref	12-18[97_0]
3-5	74-84	expression	_	_	_	_
3-6	85-87	by	_	_	_	_
3-7	88-96	multiple	abstract[8]	new[8]	_	_
3-8	97-110	transcription	abstract|abstract[8]	giv|new[8]	coref	5-3
3-9	111-118	factors	abstract[8]	new[8]	_	_
3-10	119-120	,	_	_	_	_
3-11	121-130	cofactors	person	new	_	_
3-12	131-134	and	_	_	_	_
3-13	135-144	chromatin	substance|substance[11]	new|new[11]	coref|coref	8-18|8-18
3-14	145-155	regulators	substance[11]	new[11]	_	_
3-15	156-165	establish	_	_	_	_
3-16	166-169	and	_	_	_	_
3-17	170-179	maintains	_	_	_	_
3-18	180-181	a	abstract[12]	new[12]	_	_
3-19	182-190	specific	abstract[12]	new[12]	_	_
3-20	191-196	state	abstract[12]	new[12]	_	_
3-21	197-199	of	abstract[12]	new[12]	_	_
3-22	200-201	a	abstract[12]|place[13]	new[12]|new[13]	coref	15-10[0_13]
3-23	202-206	cell	abstract[12]|place[13]	new[12]|new[13]	_	_
3-24	207-208	.	_	_	_	_

#Text=Inaccurate regulation of transmitted signals can results in diseases and severe disorders .
4-1	209-219	Inaccurate	abstract[14]	new[14]	coref	9-12[54_14]
4-2	220-230	regulation	abstract[14]	new[14]	_	_
4-3	231-233	of	abstract[14]	new[14]	_	_
4-4	234-245	transmitted	abstract[14]|abstract[15]	new[14]|new[15]	_	_
4-5	246-253	signals	abstract[14]|abstract[15]	new[14]|new[15]	_	_
4-6	254-257	can	_	_	_	_
4-7	258-265	results	abstract[16]	new[16]	_	_
4-8	266-268	in	abstract[16]	new[16]	_	_
4-9	269-277	diseases	abstract[16]|abstract	new[16]|new	_	_
4-10	278-281	and	abstract[16]	new[16]	_	_
4-11	282-288	severe	abstract[16]|abstract[18]	new[16]|new[18]	_	_
4-12	289-298	disorders	abstract[16]|abstract[18]	new[16]|new[18]	_	_
4-13	299-300	.	_	_	_	_

#Text=Therefore , transcription requires balanced orchestration of adjustable complexes of proteins .
5-1	301-310	Therefore	_	_	_	_
5-2	311-312	,	_	_	_	_
5-3	313-326	transcription	abstract	giv	coref	6-5
5-4	327-335	requires	_	_	_	_
5-5	336-344	balanced	abstract[20]	new[20]	_	_
5-6	345-358	orchestration	abstract[20]	new[20]	_	_
5-7	359-361	of	abstract[20]	new[20]	_	_
5-8	362-372	adjustable	abstract[20]|abstract[21]	new[20]|new[21]	_	_
5-9	373-382	complexes	abstract[20]|abstract[21]	new[20]|new[21]	_	_
5-10	383-385	of	abstract[20]|abstract[21]	new[20]|new[21]	_	_
5-11	386-394	proteins	abstract[20]|abstract[21]|substance	new[20]|new[21]|giv	coref	11-1[78_0]
5-12	395-396	.	_	_	_	_

#Text=A key regulator of transcription is Mediator , a multi-subunit Mediator complex which interacts with RNA polymerase II ( Pol II ) , and coordinates the action of numerous co-activators and co-repressors .
6-1	397-398	A	person[23]	new[23]	coref	6-7[0_23]
6-2	399-402	key	person[23]	new[23]	_	_
6-3	403-412	regulator	person[23]	new[23]	_	_
6-4	413-415	of	person[23]	new[23]	_	_
6-5	416-429	transcription	person[23]|abstract	new[23]|giv	coref	9-12
6-6	430-432	is	_	_	_	_
6-7	433-441	Mediator	person	giv	coref	6-11
6-8	442-443	,	_	_	_	_
6-9	444-445	a	abstract[27]	new[27]	_	_
6-10	446-459	multi-subunit	abstract[27]	new[27]	_	_
6-11	460-468	Mediator	person|abstract[27]	giv|new[27]	coref	7-3[36_0]
6-12	469-476	complex	abstract[27]	new[27]	_	_
6-13	477-482	which	_	_	_	_
6-14	483-492	interacts	_	_	_	_
6-15	493-497	with	_	_	_	_
6-16	498-501	RNA	substance|abstract[29]	new|new[29]	_	_
6-17	502-512	polymerase	abstract[29]	new[29]	_	_
6-18	513-515	II	abstract[29]	new[29]	_	_
6-19	516-517	(	_	_	_	_
6-20	518-521	Pol	person	new	coref	26-26[220_0]
6-21	522-524	II	person	new	_	_
6-22	525-526	)	_	_	_	_
6-23	527-528	,	_	_	_	_
6-24	529-532	and	_	_	_	_
6-25	533-544	coordinates	_	_	_	_
6-26	545-548	the	abstract[32]	new[32]	_	_
6-27	549-555	action	abstract[32]	new[32]	_	_
6-28	556-558	of	abstract[32]	new[32]	_	_
6-29	559-567	numerous	abstract[32]|person[33]	new[32]|new[33]	_	_
6-30	568-581	co-activators	abstract[32]|person[33]	new[32]|new[33]	_	_
6-31	582-585	and	abstract[32]	new[32]	_	_
6-32	586-599	co-repressors	abstract[32]|person	new[32]|new	_	_
6-33	600-601	.	_	_	_	_

#Text=Function of the Mediator is conserved in all eukaryotes , though , the individual subunits have diverged considerably in some organisms .
7-1	602-610	Function	abstract[35]	new[35]	_	_
7-2	611-613	of	abstract[35]	new[35]	_	_
7-3	614-617	the	abstract[35]|person[36]	new[35]|giv[36]	coref	8-15[46_36]
7-4	618-626	Mediator	abstract[35]|person[36]	new[35]|giv[36]	_	_
7-5	627-629	is	_	_	_	_
7-6	630-639	conserved	_	_	_	_
7-7	640-642	in	_	_	_	_
7-8	643-646	all	place[37]	new[37]	_	_
7-9	647-657	eukaryotes	place[37]	new[37]	_	_
7-10	658-659	,	_	_	_	_
7-11	660-666	though	_	_	_	_
7-12	667-668	,	_	_	_	_
7-13	669-672	the	abstract[38]	new[38]	coref	8-13[45_38]
7-14	673-683	individual	abstract[38]	new[38]	_	_
7-15	684-692	subunits	abstract[38]	new[38]	_	_
7-16	693-697	have	_	_	_	_
7-17	698-706	diverged	_	_	_	_
7-18	707-719	considerably	_	_	_	_
7-19	720-722	in	_	_	_	_
7-20	723-727	some	animal[39]	new[39]	_	_
7-21	728-737	organisms	animal[39]	new[39]	_	_
7-22	738-739	.	_	_	_	_

#Text=Up to date , for some bHLH family representatives , interactions with subunits of the Mediator and/or chromatin remodeling histone acetyltransferases/deacyltransferase , were reported .
8-1	740-742	Up	_	_	_	_
8-2	743-745	to	_	_	_	_
8-3	746-750	date	time	new	_	_
8-4	751-752	,	_	_	_	_
8-5	753-756	for	_	_	_	_
8-6	757-761	some	person[43]	new[43]	_	_
8-7	762-766	bHLH	organization|person[43]	giv|new[43]	coref	10-46
8-8	767-773	family	abstract|person[43]	new|new[43]	coref	10-45[74_0]
8-9	774-789	representatives	person[43]	new[43]	_	_
8-10	790-791	,	_	_	_	_
8-11	792-804	interactions	abstract[44]	new[44]	coref	28-33[240_44]
8-12	805-809	with	abstract[44]	new[44]	_	_
8-13	810-818	subunits	abstract[44]|abstract[45]	new[44]|giv[45]	_	_
8-14	819-821	of	abstract[44]|abstract[45]	new[44]|giv[45]	_	_
8-15	822-825	the	abstract[44]|abstract[45]|person[46]	new[44]|giv[45]|giv[46]	coref	9-4[51_46]
8-16	826-834	Mediator	abstract[44]|abstract[45]|person[46]	new[44]|giv[45]|giv[46]	_	_
8-17	835-841	and/or	abstract[48]	new[48]	coref	18-17[0_48]
8-18	842-851	chromatin	substance|abstract[48]	giv|new[48]	coref	18-34
8-19	852-862	remodeling	abstract[48]	new[48]	_	_
8-20	863-870	histone	abstract[48]	new[48]	_	_
8-21	871-907	acetyltransferases/deacyltransferase	abstract[48]|substance	new[48]|new	_	_
8-22	908-909	,	_	_	_	_
8-23	910-914	were	_	_	_	_
8-24	915-923	reported	_	_	_	_
8-25	924-925	.	_	_	_	_

#Text=In plants , the Mediator complex is a core element of transcription regulation important for their immunity .
9-1	926-928	In	_	_	_	_
9-2	929-935	plants	plant	new	ana	9-16
9-3	936-937	,	_	_	_	_
9-4	938-941	the	person[51]	giv[51]	coref	10-28[66_51]
9-5	942-950	Mediator	person[51]	giv[51]	_	_
9-6	951-958	complex	person[51]	giv[51]	_	_
9-7	959-961	is	_	_	_	_
9-8	962-963	a	abstract[52]	new[52]	coref	11-1[76_52]
9-9	964-968	core	abstract[52]	new[52]	_	_
9-10	969-976	element	abstract[52]	new[52]	_	_
9-11	977-979	of	abstract[52]	new[52]	_	_
9-12	980-993	transcription	abstract[52]|abstract|abstract[54]	new[52]|giv|giv[54]	coref|coref	11-19|11-19
9-13	994-1004	regulation	abstract[52]|abstract[54]	new[52]|giv[54]	_	_
9-14	1005-1014	important	abstract[52]	new[52]	_	_
9-15	1015-1018	for	_	_	_	_
9-16	1019-1024	their	plant|abstract[56]	giv|new[56]	ana|ana	10-1[0_56]|10-1[0_56]
9-17	1025-1033	immunity	abstract[56]	new[56]	_	_
9-18	1034-1035	.	_	_	_	_

#Text=It was shown , that in Arabidopsis thaliana important jasmonate signaling and resistance to fungus Botrytis cinerea , is dependent on the interaction between MED25 subunit of the Mediator and MYC2 , and interaction of MED8 subunit of the Mediator with FAMA belonging to the bHLH family .
10-1	1036-1038	It	abstract	giv	_	_
10-2	1039-1042	was	_	_	_	_
10-3	1043-1048	shown	_	_	_	_
10-4	1049-1050	,	_	_	_	_
10-5	1051-1055	that	_	_	_	_
10-6	1056-1058	in	_	_	_	_
10-7	1059-1070	Arabidopsis	abstract	new	_	_
10-8	1071-1079	thaliana	abstract[60]	new[60]	_	_
10-9	1080-1089	important	abstract[60]	new[60]	_	_
10-10	1090-1099	jasmonate	abstract|abstract[60]	new|new[60]	_	_
10-11	1100-1109	signaling	abstract[60]	new[60]	_	_
10-12	1110-1113	and	_	_	_	_
10-13	1114-1124	resistance	abstract[61]	new[61]	_	_
10-14	1125-1127	to	abstract[61]	new[61]	_	_
10-15	1128-1134	fungus	abstract[61]|plant	new[61]|new	_	_
10-16	1135-1143	Botrytis	_	_	_	_
10-17	1144-1151	cinerea	_	_	_	_
10-18	1152-1153	,	_	_	_	_
10-19	1154-1156	is	_	_	_	_
10-20	1157-1166	dependent	_	_	_	_
10-21	1167-1169	on	_	_	_	_
10-22	1170-1173	the	abstract[63]	new[63]	coref	21-6[178_63]
10-23	1174-1185	interaction	abstract[63]	new[63]	_	_
10-24	1186-1193	between	abstract[63]	new[63]	_	_
10-25	1194-1199	MED25	abstract[63]|abstract|abstract[65]	new[63]|new|new[65]	_	_
10-26	1200-1207	subunit	abstract[63]|abstract[65]	new[63]|new[65]	_	_
10-27	1208-1210	of	abstract[63]|abstract[65]	new[63]|new[65]	_	_
10-28	1211-1214	the	abstract[63]|abstract[65]|person[66]	new[63]|new[65]|giv[66]	coref	10-39[71_66]
10-29	1215-1223	Mediator	abstract[63]|abstract[65]|person[66]	new[63]|new[65]|giv[66]	_	_
10-30	1224-1227	and	abstract[63]|abstract[65]	new[63]|new[65]	_	_
10-31	1228-1232	MYC2	abstract[63]|abstract[65]|object	new[63]|new[65]|new	_	_
10-32	1233-1234	,	_	_	_	_
10-33	1235-1238	and	_	_	_	_
10-34	1239-1250	interaction	abstract[68]	new[68]	_	_
10-35	1251-1253	of	abstract[68]	new[68]	_	_
10-36	1254-1258	MED8	abstract[68]|abstract|organization[70]	new[68]|new|new[70]	_	_
10-37	1259-1266	subunit	abstract[68]|organization[70]	new[68]|new[70]	_	_
10-38	1267-1269	of	abstract[68]|organization[70]	new[68]|new[70]	_	_
10-39	1270-1273	the	abstract[68]|organization[70]|person[71]	new[68]|new[70]|giv[71]	coref	12-14[96_71]
10-40	1274-1282	Mediator	abstract[68]|organization[70]|person[71]	new[68]|new[70]|giv[71]	_	_
10-41	1283-1287	with	abstract[68]|organization[70]|person[71]	new[68]|new[70]|giv[71]	_	_
10-42	1288-1292	FAMA	abstract[68]|organization[70]|person[71]|abstract	new[68]|new[70]|giv[71]|new	_	_
10-43	1293-1302	belonging	_	_	_	_
10-44	1303-1305	to	_	_	_	_
10-45	1306-1309	the	abstract[74]	giv[74]	_	_
10-46	1310-1314	bHLH	person|abstract[74]	giv|giv[74]	coref	11-12
10-47	1315-1321	family	abstract[74]	giv[74]	_	_
10-48	1322-1323	.	_	_	_	_

#Text=Sterol regulatory element binding proteins ( SREBPs ) the class II bHLH TFs ( Table 1 ) are transcription activators critical for regulation of cholesterol and fatty acid homeostasis in animals .
11-1	1324-1330	Sterol	abstract|abstract[76]|substance[78]	new|giv[76]|giv[78]	coref|coref|coref	11-19[84_78]|11-19[84_78]|11-19[84_78]
11-2	1331-1341	regulatory	abstract[76]|substance[78]	giv[76]|giv[78]	_	_
11-3	1342-1349	element	abstract[76]|substance[78]	giv[76]|giv[78]	_	_
11-4	1350-1357	binding	object|substance[78]	new|giv[78]	_	_
11-5	1358-1366	proteins	substance[78]	giv[78]	_	_
11-6	1367-1368	(	_	_	_	_
11-7	1369-1375	SREBPs	object	new	coref	12-5[91_0]
11-8	1376-1377	)	_	_	_	_
11-9	1378-1381	the	abstract[80]	new[80]	coref	18-41[147_80]
11-10	1382-1387	class	abstract[80]	new[80]	_	_
11-11	1388-1390	II	_	_	_	_
11-12	1391-1395	bHLH	abstract	giv	coref	28-11
11-13	1396-1399	TFs	_	_	_	_
11-14	1400-1401	(	_	_	_	_
11-15	1402-1407	Table	object	new	coref	14-9[108_0]
11-16	1408-1409	1	_	_	_	_
11-17	1410-1411	)	_	_	_	_
11-18	1412-1415	are	_	_	_	_
11-19	1416-1429	transcription	abstract|substance[84]	giv|giv[84]	coref|coref|coref|coref	23-5[0_84]|23-19|23-5[0_84]|23-19
11-20	1430-1440	activators	substance[84]	giv[84]	_	_
11-21	1441-1449	critical	substance[84]	giv[84]	_	_
11-22	1450-1453	for	_	_	_	_
11-23	1454-1464	regulation	abstract[85]	new[85]	_	_
11-24	1465-1467	of	abstract[85]	new[85]	_	_
11-25	1468-1479	cholesterol	abstract[85]|substance	new[85]|new	_	_
11-26	1480-1483	and	abstract[85]	new[85]	_	_
11-27	1484-1489	fatty	abstract[85]|abstract[88]	new[85]|new[88]	ana	12-1[0_88]
11-28	1490-1494	acid	abstract[85]|substance|abstract[88]	new[85]|new|new[88]	_	_
11-29	1495-1506	homeostasis	abstract[85]|abstract[88]	new[85]|new[88]	_	_
11-30	1507-1509	in	abstract[85]|abstract[88]	new[85]|new[88]	_	_
11-31	1510-1517	animals	abstract[85]|abstract[88]|animal	new[85]|new[88]|new	_	_
11-32	1518-1519	.	_	_	_	_

#Text=It was shown that human SREBPs bind CBP/p300 acetyltransferase and MED15 subunit of the Mediator to activate target genes .
12-1	1520-1522	It	abstract	giv	_	_
12-2	1523-1526	was	_	_	_	_
12-3	1527-1532	shown	_	_	_	_
12-4	1533-1537	that	_	_	_	_
12-5	1538-1543	human	object[91]	giv[91]	_	_
12-6	1544-1550	SREBPs	object[91]	giv[91]	_	_
12-7	1551-1555	bind	_	_	_	_
12-8	1556-1564	CBP/p300	abstract|object[93]	new|new[93]	coref|coref|coref|coref	17-4|17-4[130_93]|17-4|17-4[130_93]
12-9	1565-1582	acetyltransferase	object[93]	new[93]	_	_
12-10	1583-1586	and	_	_	_	_
12-11	1587-1592	MED15	time|organization[95]	new|new[95]	coref|coref	13-8|13-8
12-12	1593-1600	subunit	organization[95]	new[95]	_	_
12-13	1601-1603	of	organization[95]	new[95]	_	_
12-14	1604-1607	the	organization[95]|organization[96]	new[95]|giv[96]	coref	13-12[0_96]
12-15	1608-1616	Mediator	organization[95]|organization[96]	new[95]|giv[96]	_	_
12-16	1617-1619	to	_	_	_	_
12-17	1620-1628	activate	_	_	_	_
12-18	1629-1635	target	abstract[97]	giv[97]	_	_
12-19	1636-1641	genes	abstract[97]	giv[97]	_	_
12-20	1642-1643	.	_	_	_	_

#Text=Also yeast Ino2 was shown to bind MED15 subunit of the Mediator tail .
13-1	1644-1648	Also	_	_	_	_
13-2	1649-1654	yeast	substance|abstract[99]	new|new[99]	_	_
13-3	1655-1659	Ino2	abstract[99]	new[99]	_	_
13-4	1660-1663	was	_	_	_	_
13-5	1664-1669	shown	_	_	_	_
13-6	1670-1672	to	_	_	_	_
13-7	1673-1677	bind	_	_	_	_
13-8	1678-1683	MED15	time|object[101]	giv|new[101]	_	_
13-9	1684-1691	subunit	object[101]	new[101]	_	_
13-10	1692-1694	of	object[101]	new[101]	_	_
13-11	1695-1698	the	object[101]|object[103]	new[101]|new[103]	_	_
13-12	1699-1707	Mediator	object[101]|person|object[103]	new[101]|giv|new[103]	_	_
13-13	1708-1712	tail	object[101]|object[103]	new[101]|new[103]	_	_
13-14	1713-1714	.	_	_	_	_

#Text=The representative of class II TFs TAL1 ( Table 1 ) is required for the specification of the blood lineage and maturation of several hematopoietic cells .
14-1	1715-1718	The	person[104]	new[104]	_	_
14-2	1719-1733	representative	person[104]	new[104]	_	_
14-3	1734-1736	of	person[104]	new[104]	_	_
14-4	1737-1742	class	person[104]|person[105]	new[104]|new[105]	_	_
14-5	1743-1745	II	person[104]|person[105]	new[104]|new[105]	_	_
14-6	1746-1749	TFs	abstract|abstract[107]	new|new[107]	coref|coref|coref|coref	16-3[124_0]|17-1[0_107]|16-3[124_0]|17-1[0_107]
14-7	1750-1754	TAL1	abstract[107]	new[107]	_	_
14-8	1755-1756	(	_	_	_	_
14-9	1757-1762	Table	object[108]	giv[108]	coref	18-44[149_108]
14-10	1763-1764	1	object[108]	giv[108]	_	_
14-11	1765-1766	)	_	_	_	_
14-12	1767-1769	is	_	_	_	_
14-13	1770-1778	required	_	_	_	_
14-14	1779-1782	for	_	_	_	_
14-15	1783-1786	the	abstract[109]	new[109]	_	_
14-16	1787-1800	specification	abstract[109]	new[109]	_	_
14-17	1801-1803	of	abstract[109]	new[109]	_	_
14-18	1804-1807	the	abstract[109]|abstract[111]	new[109]|new[111]	_	_
14-19	1808-1813	blood	abstract[109]|substance|abstract[111]	new[109]|new|new[111]	_	_
14-20	1814-1821	lineage	abstract[109]|abstract[111]	new[109]|new[111]	_	_
14-21	1822-1825	and	abstract[109]	new[109]	_	_
14-22	1826-1836	maturation	abstract[109]|event[112]	new[109]|new[112]	_	_
14-23	1837-1839	of	abstract[109]|event[112]	new[109]|new[112]	_	_
14-24	1840-1847	several	abstract[109]|event[112]|object[113]	new[109]|new[112]|new[113]	coref	15-18[121_113]
14-25	1848-1861	hematopoietic	abstract[109]|event[112]|object[113]	new[109]|new[112]|new[113]	_	_
14-26	1862-1867	cells	abstract[109]|event[112]|object[113]	new[109]|new[112]|new[113]	_	_
14-27	1868-1869	.	_	_	_	_

#Text=TAL1/SCL is considered as a master TF delineating the cell fate and the identity of progenitor and normal hematopoietic stem cells ( HSCs ) .
15-1	1870-1878	TAL1/SCL	abstract	new	_	_
15-2	1879-1881	is	_	_	_	_
15-3	1882-1892	considered	_	_	_	_
15-4	1893-1895	as	_	_	_	_
15-5	1896-1897	a	abstract[115]	new[115]	_	_
15-6	1898-1904	master	abstract[115]	new[115]	_	_
15-7	1905-1907	TF	abstract[115]	new[115]	_	_
15-8	1908-1919	delineating	_	_	_	_
15-9	1920-1923	the	abstract[117]	new[117]	_	_
15-10	1924-1928	cell	place|abstract[117]	giv|new[117]	coref	16-11
15-11	1929-1933	fate	abstract[117]	new[117]	_	_
15-12	1934-1937	and	_	_	_	_
15-13	1938-1941	the	abstract[118]	new[118]	_	_
15-14	1942-1950	identity	abstract[118]	new[118]	_	_
15-15	1951-1953	of	abstract[118]	new[118]	_	_
15-16	1954-1964	progenitor	abstract[118]|person	new[118]|new	_	_
15-17	1965-1968	and	abstract[118]	new[118]	_	_
15-18	1969-1975	normal	abstract[118]|object[121]	new[118]|giv[121]	_	_
15-19	1976-1989	hematopoietic	abstract[118]|object[121]	new[118]|giv[121]	_	_
15-20	1990-1994	stem	abstract[118]|plant|object[121]	new[118]|new|giv[121]	_	_
15-21	1995-2000	cells	abstract[118]|object[121]	new[118]|giv[121]	_	_
15-22	2001-2002	(	_	_	_	_
15-23	2003-2007	HSCs	place	new	ana	16-1
15-24	2008-2009	)	_	_	_	_
15-25	2010-2011	.	_	_	_	_

#Text=It regulates other hematopoietic TFs thus has a potential for cell reprogramming .
16-1	2012-2014	It	place	giv	_	_
16-2	2015-2024	regulates	_	_	_	_
16-3	2025-2030	other	abstract[124]	giv[124]	coref	18-64[0_124]
16-4	2031-2044	hematopoietic	abstract[124]	giv[124]	_	_
16-5	2045-2048	TFs	abstract[124]	giv[124]	_	_
16-6	2049-2053	thus	_	_	_	_
16-7	2054-2057	has	_	_	_	_
16-8	2058-2059	a	abstract[125]	new[125]	_	_
16-9	2060-2069	potential	abstract[125]	new[125]	_	_
16-10	2070-2073	for	abstract[125]	new[125]	_	_
16-11	2074-2078	cell	abstract[125]|place|abstract[127]	new[125]|giv|new[127]	coref|coref	20-3|20-3
16-12	2079-2092	reprogramming	abstract[125]|abstract[127]	new[125]|new[127]	_	_
16-13	2093-2094	.	_	_	_	_

#Text=TAL1 also binds CBP/p300 acetyltransferase .
17-1	2095-2099	TAL1	abstract	giv	_	_
17-2	2100-2104	also	_	_	_	_
17-3	2105-2110	binds	_	_	_	_
17-4	2111-2119	CBP/p300	abstract|substance[130]	giv|giv[130]	coref|coref	18-17[138_130]|18-17[138_130]
17-5	2120-2137	acetyltransferase	substance[130]	giv[130]	_	_
17-6	2138-2139	.	_	_	_	_

#Text=Similarly MyoD — a myogenic regulatory factor which controls skeletal muscle development binds CBP and recruits histone acetyltransferase to activate myogenic program . Cao et al. showed that of MyoD modify the myoblasts chromatin structure and accessibility . ASCL1 ( class II , Table 1 ) was shown to be a pioneer factor which promotes chromatin accessibility and enables chromatin binding by others TFs .
18-1	2140-2149	Similarly	_	_	_	_
18-2	2150-2154	MyoD	abstract	new	coref	18-30
18-3	2155-2156	—	_	_	_	_
18-4	2157-2158	a	abstract[132]	new[132]	coref	18-51[150_132]
18-5	2159-2167	myogenic	abstract[132]	new[132]	_	_
18-6	2168-2178	regulatory	abstract[132]	new[132]	_	_
18-7	2179-2185	factor	abstract[132]	new[132]	_	_
18-8	2186-2191	which	_	_	_	_
18-9	2192-2200	controls	_	_	_	_
18-10	2201-2209	skeletal	event[134]	new[134]	_	_
18-11	2210-2216	muscle	object|event[134]	new|new[134]	_	_
18-12	2217-2228	development	event[134]	new[134]	_	_
18-13	2229-2234	binds	_	_	_	_
18-14	2235-2238	CBP	object	new	_	_
18-15	2239-2242	and	_	_	_	_
18-16	2243-2251	recruits	plant[136]	new[136]	_	_
18-17	2252-2259	histone	plant[136]|abstract|object[138]	new[136]|giv|giv[138]	coref|coref|coref|coref	21-19|21-20[0_138]|21-19|21-20[0_138]
18-18	2260-2277	acetyltransferase	plant[136]|object[138]	new[136]|giv[138]	_	_
18-19	2278-2280	to	_	_	_	_
18-20	2281-2289	activate	_	_	_	_
18-21	2290-2298	myogenic	event[139]	new[139]	_	_
18-22	2299-2306	program	event[139]	new[139]	_	_
18-23	2307-2308	.	_	_	_	_
18-24	2309-2312	Cao	person	new	_	_
18-25	2313-2315	et	_	_	_	_
18-26	2316-2319	al.	_	_	_	_
18-27	2320-2326	showed	_	_	_	_
18-28	2327-2331	that	_	_	_	_
18-29	2332-2334	of	_	_	_	_
18-30	2335-2339	MyoD	abstract	giv	_	_
18-31	2340-2346	modify	_	_	_	_
18-32	2347-2350	the	abstract[144]	new[144]	_	_
18-33	2351-2360	myoblasts	abstract|abstract[144]	new|new[144]	_	_
18-34	2361-2370	chromatin	substance|abstract[144]	giv|new[144]	coref	18-56
18-35	2371-2380	structure	abstract[144]	new[144]	_	_
18-36	2381-2384	and	_	_	_	_
18-37	2385-2398	accessibility	abstract	new	coref	18-56[152_0]
18-38	2399-2400	.	_	_	_	_
18-39	2401-2406	ASCL1	person	new	appos	18-41[148_0]
18-40	2407-2408	(	_	_	_	_
18-41	2409-2414	class	abstract[147]|person[148]	giv[147]|giv[148]	coref|coref	23-8[197_147]|23-8[197_147]
18-42	2415-2417	II	abstract[147]|person[148]	giv[147]|giv[148]	_	_
18-43	2418-2419	,	person[148]	giv[148]	_	_
18-44	2420-2425	Table	person[148]|object[149]	giv[148]|giv[149]	coref	19-8[0_149]
18-45	2426-2427	1	person[148]|object[149]	giv[148]|giv[149]	_	_
18-46	2428-2429	)	_	_	_	_
18-47	2430-2433	was	_	_	_	_
18-48	2434-2439	shown	_	_	_	_
18-49	2440-2442	to	_	_	_	_
18-50	2443-2445	be	_	_	_	_
18-51	2446-2447	a	abstract[150]	giv[150]	coref	19-15[159_150]
18-52	2448-2455	pioneer	abstract[150]	giv[150]	_	_
18-53	2456-2462	factor	abstract[150]	giv[150]	_	_
18-54	2463-2468	which	_	_	_	_
18-55	2469-2477	promotes	_	_	_	_
18-56	2478-2487	chromatin	abstract|abstract[152]	giv|giv[152]	coref|coref	18-60|18-60
18-57	2488-2501	accessibility	abstract[152]	giv[152]	_	_
18-58	2502-2505	and	_	_	_	_
18-59	2506-2513	enables	_	_	_	_
18-60	2514-2523	chromatin	substance	giv	_	_
18-61	2524-2531	binding	_	_	_	_
18-62	2532-2534	by	_	_	_	_
18-63	2535-2541	others	person	new	_	_
18-64	2542-2545	TFs	abstract	giv	coref	24-14[207_0]
18-65	2546-2547	.	_	_	_	_

#Text=Recently , also AHR ( bHLH-PAS , Table 1 ) was suggested to be a pioneer factor which regulates DNA methylation during embryonic developments in unknown way .
19-1	2548-2556	Recently	_	_	_	_
19-2	2557-2558	,	_	_	_	_
19-3	2559-2563	also	_	_	_	_
19-4	2564-2567	AHR	abstract	new	appos	19-6[157_0]
19-5	2568-2569	(	_	_	_	_
19-6	2570-2578	bHLH-PAS	abstract[157]	giv[157]	_	_
19-7	2579-2580	,	abstract[157]	giv[157]	_	_
19-8	2581-2586	Table	abstract[157]|abstract	giv[157]|giv	coref	21-15
19-9	2587-2588	1	abstract[157]	giv[157]	_	_
19-10	2589-2590	)	_	_	_	_
19-11	2591-2594	was	_	_	_	_
19-12	2595-2604	suggested	_	_	_	_
19-13	2605-2607	to	_	_	_	_
19-14	2608-2610	be	_	_	_	_
19-15	2611-2612	a	abstract[159]	giv[159]	coref	27-28[230_159]
19-16	2613-2620	pioneer	abstract[159]	giv[159]	_	_
19-17	2621-2627	factor	abstract[159]	giv[159]	_	_
19-18	2628-2633	which	_	_	_	_
19-19	2634-2643	regulates	_	_	_	_
19-20	2644-2647	DNA	substance|abstract[161]	new|new[161]	coref|coref	24-6[204_0]|24-6[204_0]
19-21	2648-2659	methylation	abstract[161]	new[161]	_	_
19-22	2660-2666	during	_	_	_	_
19-23	2667-2676	embryonic	event[162]	new[162]	_	_
19-24	2677-2689	developments	event[162]	new[162]	_	_
19-25	2690-2692	in	event[162]	new[162]	_	_
19-26	2693-2700	unknown	event[162]|abstract[163]	new[162]|new[163]	coref	25-13[211_163]
19-27	2701-2704	way	event[162]|abstract[163]	new[162]|new[163]	_	_
19-28	2705-2706	.	_	_	_	_

#Text=In clear cell renal cell carcinoma ( ccRCC ) , the most frequent mutation causes the von Hippel-Lindau ( VHL ) tumor suppressor inactivation leading to genome-wide enhancer and super-enhancer remodeling .
20-1	2707-2709	In	_	_	_	_
20-2	2710-2715	clear	abstract[165]|object[167]	new[165]|new[167]	_	_
20-3	2716-2720	cell	place|abstract[165]|object[167]	giv|new[165]|new[167]	coref	20-5
20-4	2721-2726	renal	abstract[165]|object[167]	new[165]|new[167]	_	_
20-5	2727-2731	cell	place|object[167]	giv|new[167]	coref	28-24
20-6	2732-2741	carcinoma	object[167]	new[167]	_	_
20-7	2742-2743	(	_	_	_	_
20-8	2744-2749	ccRCC	place	new	_	_
20-9	2750-2751	)	_	_	_	_
20-10	2752-2753	,	_	_	_	_
20-11	2754-2757	the	abstract[169]	new[169]	_	_
20-12	2758-2762	most	abstract[169]	new[169]	_	_
20-13	2763-2771	frequent	abstract[169]	new[169]	_	_
20-14	2772-2780	mutation	abstract[169]	new[169]	_	_
20-15	2781-2787	causes	_	_	_	_
20-16	2788-2791	the	person[170]	new[170]	_	_
20-17	2792-2795	von	person[170]	new[170]	_	_
20-18	2796-2809	Hippel-Lindau	person[170]	new[170]	_	_
20-19	2810-2811	(	_	_	_	_
20-20	2812-2815	VHL	abstract	new	_	_
20-21	2816-2817	)	_	_	_	_
20-22	2818-2823	tumor	abstract|event[174]	new|new[174]	_	_
20-23	2824-2834	suppressor	object|event[174]	new|new[174]	_	_
20-24	2835-2847	inactivation	event[174]	new[174]	_	_
20-25	2848-2855	leading	_	_	_	_
20-26	2856-2858	to	_	_	_	_
20-27	2859-2870	genome-wide	abstract[175]	new[175]	_	_
20-28	2871-2879	enhancer	abstract[175]	new[175]	_	_
20-29	2880-2883	and	_	_	_	_
20-30	2884-2898	super-enhancer	event[176]	new[176]	_	_
20-31	2899-2909	remodeling	event[176]	new[176]	_	_
20-32	2910-2911	.	_	_	_	_

#Text=This process is mediated by the interaction of HIF2α and HIF1β ( bHLH-PAS , Table 1 ) with histone acetyltransferase p300 .
21-1	2912-2916	This	event[177]	new[177]	_	_
21-2	2917-2924	process	event[177]	new[177]	_	_
21-3	2925-2927	is	_	_	_	_
21-4	2928-2936	mediated	_	_	_	_
21-5	2937-2939	by	_	_	_	_
21-6	2940-2943	the	abstract[178]	giv[178]	appos	21-12[181_178]
21-7	2944-2955	interaction	abstract[178]	giv[178]	_	_
21-8	2956-2958	of	abstract[178]	giv[178]	_	_
21-9	2959-2964	HIF2α	abstract[178]|abstract	giv[178]|new	_	_
21-10	2965-2968	and	abstract[178]	giv[178]	_	_
21-11	2969-2974	HIF1β	abstract[178]|abstract	giv[178]|new	_	_
21-12	2975-2976	(	abstract[181]	giv[181]	coref	22-5[0_181]
21-13	2977-2985	bHLH-PAS	abstract[181]	giv[181]	_	_
21-14	2986-2987	,	abstract[181]	giv[181]	_	_
21-15	2988-2993	Table	abstract[181]|abstract	giv[181]|giv	coref	22-9
21-16	2994-2995	1	abstract[181]	giv[181]	_	_
21-17	2996-2997	)	abstract[181]	giv[181]	_	_
21-18	2998-3002	with	abstract[181]	giv[181]	_	_
21-19	3003-3010	histone	abstract[181]|abstract|place[185]	giv[181]|giv|new[185]	coref|coref	22-16|22-16
21-20	3011-3028	acetyltransferase	abstract[181]|object|place[185]	giv[181]|giv|new[185]	_	_
21-21	3029-3033	p300	abstract[181]|place[185]	giv[181]|new[185]	_	_
21-22	3034-3035	.	_	_	_	_

#Text=CLOCK , the other bHLH-PAS subfamily member ( Table 1 ) was shown to mediate histone acetylation in a circadian time-specific manner .
22-1	3036-3041	CLOCK	object	new	_	_
22-2	3042-3043	,	_	_	_	_
22-3	3044-3047	the	person[188]	new[188]	appos	22-9[190_188]
22-4	3048-3053	other	person[188]	new[188]	_	_
22-5	3054-3062	bHLH-PAS	abstract|person[188]	giv|new[188]	_	_
22-6	3063-3072	subfamily	person[188]	new[188]	_	_
22-7	3073-3079	member	person[188]	new[188]	_	_
22-8	3080-3081	(	_	_	_	_
22-9	3082-3087	Table	abstract|abstract[190]	giv|giv[190]	coref|coref	23-3[196_190]|23-3[196_190]
22-10	3088-3089	1	abstract[190]	giv[190]	_	_
22-11	3090-3091	)	_	_	_	_
22-12	3092-3095	was	_	_	_	_
22-13	3096-3101	shown	_	_	_	_
22-14	3102-3104	to	_	_	_	_
22-15	3105-3112	mediate	_	_	_	_
22-16	3113-3120	histone	abstract|abstract[192]	giv|new[192]	coref|coref	24-11|24-11
22-17	3121-3132	acetylation	abstract[192]	new[192]	_	_
22-18	3133-3135	in	_	_	_	_
22-19	3136-3137	a	abstract[193]	new[193]	_	_
22-20	3138-3147	circadian	abstract[193]	new[193]	_	_
22-21	3148-3161	time-specific	abstract[193]	new[193]	_	_
22-22	3162-3168	manner	abstract[193]	new[193]	_	_
22-23	3169-3170	.	_	_	_	_

#Text=Interestingly , the bHLH-O proteins members ( class VI , Table 1 ) HEY proteins can function as transcription repressors as well as transcription activators .
23-1	3171-3184	Interestingly	_	_	_	_
23-2	3185-3186	,	_	_	_	_
23-3	3187-3190	the	person[196]	giv[196]	ana	24-1[0_196]
23-4	3191-3197	bHLH-O	event|person[196]	new|giv[196]	_	_
23-5	3198-3206	proteins	substance|person[196]	giv|giv[196]	coref	23-14[200_0]
23-6	3207-3214	members	person[196]	giv[196]	_	_
23-7	3215-3216	(	_	_	_	_
23-8	3217-3222	class	abstract[197]	giv[197]	_	_
23-9	3223-3225	VI	abstract[197]|person	giv[197]|new	_	_
23-10	3226-3227	,	_	_	_	_
23-11	3228-3233	Table	_	_	_	_
23-12	3234-3235	1	_	_	_	_
23-13	3236-3237	)	_	_	_	_
23-14	3238-3241	HEY	abstract|substance[200]	new|giv[200]	coref|coref|coref|coref	25-9|28-10[234_200]|25-9|28-10[234_200]
23-15	3242-3250	proteins	substance[200]	giv[200]	_	_
23-16	3251-3254	can	_	_	_	_
23-17	3255-3263	function	_	_	_	_
23-18	3264-3266	as	_	_	_	_
23-19	3267-3280	transcription	abstract	giv	coref	23-24
23-20	3281-3291	repressors	_	_	_	_
23-21	3292-3294	as	_	_	_	_
23-22	3295-3299	well	_	_	_	_
23-23	3300-3302	as	_	_	_	_
23-24	3303-3316	transcription	abstract	giv	coref	27-8
23-25	3317-3327	activators	_	_	_	_
23-26	3328-3329	.	_	_	_	_

#Text=They were shown to bind directly DNA and interact with histone deacetylases and other TFs .
24-1	3330-3334	They	person	giv	_	_
24-2	3335-3339	were	_	_	_	_
24-3	3340-3345	shown	_	_	_	_
24-4	3346-3348	to	_	_	_	_
24-5	3349-3353	bind	_	_	_	_
24-6	3354-3362	directly	substance[204]	giv[204]	_	_
24-7	3363-3366	DNA	substance[204]	giv[204]	_	_
24-8	3367-3370	and	_	_	_	_
24-9	3371-3379	interact	_	_	_	_
24-10	3380-3384	with	_	_	_	_
24-11	3385-3392	histone	abstract|abstract[206]	giv|new[206]	_	_
24-12	3393-3405	deacetylases	abstract[206]	new[206]	_	_
24-13	3406-3409	and	_	_	_	_
24-14	3410-3415	other	abstract[207]	giv[207]	coref	27-4[221_207]
24-15	3416-3419	TFs	abstract[207]	giv[207]	_	_
24-16	3420-3421	.	_	_	_	_

#Text=On the other hand , gene activation by HEY is regulated in an indirect way .
25-1	3422-3424	On	_	_	_	_
25-2	3425-3428	the	_	_	_	_
25-3	3429-3434	other	_	_	_	_
25-4	3435-3439	hand	_	_	_	_
25-5	3440-3441	,	_	_	_	_
25-6	3442-3446	gene	abstract|abstract[209]	new|new[209]	_	_
25-7	3447-3457	activation	abstract[209]	new[209]	_	_
25-8	3458-3460	by	abstract[209]	new[209]	_	_
25-9	3461-3464	HEY	abstract[209]|abstract	new[209]|giv	coref	26-2
25-10	3465-3467	is	_	_	_	_
25-11	3468-3477	regulated	_	_	_	_
25-12	3478-3480	in	_	_	_	_
25-13	3481-3483	an	abstract[211]	giv[211]	_	_
25-14	3484-3492	indirect	abstract[211]	giv[211]	_	_
25-15	3493-3496	way	abstract[211]	giv[211]	_	_
25-16	3497-3498	.	_	_	_	_

#Text=Multiple HEY binding sites located downstream and close to the transcriptional start site , resulted in a hypothesis that HEY influence the pausing/elongation switch of Pol II .
26-1	3499-3507	Multiple	place[213]	new[213]	_	_
26-2	3508-3511	HEY	abstract|place[213]	giv|new[213]	_	_
26-3	3512-3519	binding	place[213]	new[213]	_	_
26-4	3520-3525	sites	place[213]	new[213]	_	_
26-5	3526-3533	located	_	_	_	_
26-6	3534-3544	downstream	place	new	_	_
26-7	3545-3548	and	_	_	_	_
26-8	3549-3554	close	_	_	_	_
26-9	3555-3557	to	_	_	_	_
26-10	3558-3561	the	place[216]	new[216]	_	_
26-11	3562-3577	transcriptional	place[216]	new[216]	_	_
26-12	3578-3583	start	event|place[216]	new|new[216]	_	_
26-13	3584-3588	site	place[216]	new[216]	_	_
26-14	3589-3590	,	_	_	_	_
26-15	3591-3599	resulted	_	_	_	_
26-16	3600-3602	in	_	_	_	_
26-17	3603-3604	a	abstract[217]	new[217]	_	_
26-18	3605-3615	hypothesis	abstract[217]	new[217]	_	_
26-19	3616-3620	that	_	_	_	_
26-20	3621-3624	HEY	_	_	_	_
26-21	3625-3634	influence	_	_	_	_
26-22	3635-3638	the	object[219]	new[219]	_	_
26-23	3639-3657	pausing/elongation	abstract|object[219]	new|new[219]	_	_
26-24	3658-3664	switch	object[219]	new[219]	_	_
26-25	3665-3667	of	object[219]	new[219]	_	_
26-26	3668-3671	Pol	object[219]|person[220]	new[219]|giv[220]	_	_
26-27	3672-3674	II	object[219]|person[220]	new[219]|giv[220]	_	_
26-28	3675-3676	.	_	_	_	_

#Text=Interestingly , though most of TFs stimulate transcription initiation , MYC ( class III , Table 1 ) was shown to stimulate transcription elongation by recruitment of the elongation factor .
27-1	3677-3690	Interestingly	_	_	_	_
27-2	3691-3692	,	_	_	_	_
27-3	3693-3699	though	_	_	_	_
27-4	3700-3704	most	abstract[221]	giv[221]	_	_
27-5	3705-3707	of	abstract[221]	giv[221]	_	_
27-6	3708-3711	TFs	abstract[221]	giv[221]	_	_
27-7	3712-3721	stimulate	_	_	_	_
27-8	3722-3735	transcription	abstract|event[223]	giv|new[223]	coref|coref	27-23|27-23
27-9	3736-3746	initiation	event[223]	new[223]	_	_
27-10	3747-3748	,	_	_	_	_
27-11	3749-3752	MYC	abstract	new	appos	27-13[225_0]
27-12	3753-3754	(	_	_	_	_
27-13	3755-3760	class	abstract[225]	giv[225]	_	_
27-14	3761-3764	III	abstract[225]	giv[225]	_	_
27-15	3765-3766	,	_	_	_	_
27-16	3767-3772	Table	_	_	_	_
27-17	3773-3774	1	_	_	_	_
27-18	3775-3776	)	_	_	_	_
27-19	3777-3780	was	_	_	_	_
27-20	3781-3786	shown	_	_	_	_
27-21	3787-3789	to	_	_	_	_
27-22	3790-3799	stimulate	_	_	_	_
27-23	3800-3813	transcription	abstract|event[227]	giv|new[227]	coref|coref	27-29[0_227]|27-29[0_227]
27-24	3814-3824	elongation	event[227]	new[227]	_	_
27-25	3825-3827	by	_	_	_	_
27-26	3828-3839	recruitment	abstract[228]	new[228]	_	_
27-27	3840-3842	of	abstract[228]	new[228]	_	_
27-28	3843-3846	the	abstract[228]|abstract[230]	new[228]|giv[230]	_	_
27-29	3847-3857	elongation	abstract[228]|event|abstract[230]	new[228]|giv|giv[230]	_	_
27-30	3858-3864	factor	abstract[228]|abstract[230]	new[228]|giv[230]	_	_
27-31	3865-3866	.	_	_	_	_

#Text=The presented studies indicate that the crucial role of the bHLH proteins in maintaining transcriptional regulation of important developmental ( e. g. , cell differentiation ) and oncogenic pathways is dependent on the multiple interactions with basal transcriptional machinery .
28-1	3867-3870	The	abstract[231]	new[231]	_	_
28-2	3871-3880	presented	abstract[231]	new[231]	_	_
28-3	3881-3888	studies	abstract[231]	new[231]	_	_
28-4	3889-3897	indicate	_	_	_	_
28-5	3898-3902	that	_	_	_	_
28-6	3903-3906	the	abstract[232]	new[232]	_	_
28-7	3907-3914	crucial	abstract[232]	new[232]	_	_
28-8	3915-3919	role	abstract[232]	new[232]	_	_
28-9	3920-3922	of	abstract[232]	new[232]	_	_
28-10	3923-3926	the	abstract[232]|substance[234]	new[232]|giv[234]	_	_
28-11	3927-3931	bHLH	abstract[232]|abstract|substance[234]	new[232]|giv|giv[234]	_	_
28-12	3932-3940	proteins	abstract[232]|substance[234]	new[232]|giv[234]	_	_
28-13	3941-3943	in	_	_	_	_
28-14	3944-3955	maintaining	_	_	_	_
28-15	3956-3971	transcriptional	abstract[235]	new[235]	_	_
28-16	3972-3982	regulation	abstract[235]	new[235]	_	_
28-17	3983-3985	of	abstract[235]	new[235]	_	_
28-18	3986-3995	important	abstract[235]	new[235]	_	_
28-19	3996-4009	developmental	abstract[235]	new[235]	_	_
28-20	4010-4011	(	_	_	_	_
28-21	4012-4014	e.	_	_	_	_
28-22	4015-4017	g.	_	_	_	_
28-23	4018-4019	,	_	_	_	_
28-24	4020-4024	cell	place|event[237]	giv|new[237]	_	_
28-25	4025-4040	differentiation	event[237]	new[237]	_	_
28-26	4041-4042	)	_	_	_	_
28-27	4043-4046	and	_	_	_	_
28-28	4047-4056	oncogenic	abstract|place[239]	new|new[239]	_	_
28-29	4057-4065	pathways	place[239]	new[239]	_	_
28-30	4066-4068	is	_	_	_	_
28-31	4069-4078	dependent	_	_	_	_
28-32	4079-4081	on	_	_	_	_
28-33	4082-4085	the	abstract[240]	giv[240]	_	_
28-34	4086-4094	multiple	abstract[240]	giv[240]	_	_
28-35	4095-4107	interactions	abstract[240]	giv[240]	_	_
28-36	4108-4112	with	abstract[240]	giv[240]	_	_
28-37	4113-4118	basal	abstract[240]|abstract[241]	giv[240]|new[241]	_	_
28-38	4119-4134	transcriptional	abstract[240]|abstract[241]	giv[240]|new[241]	_	_
28-39	4135-4144	machinery	abstract[240]|abstract[241]	giv[240]|new[241]	_	_
28-40	4145-4146	.	_	_	_	_
